August 10, 2022
LexaGene has shortened the time the MiQLab® System needs to report a result by ~35%.
July 29, 2022
LexaGene has filed financial statements and granted incentive equity awards to employees.
July 27, 2022
LexaGene provides a summary of preliminary data collected during a clinical validation study.
July 12, 2022
LexaGene continues to make progress on Annual Financial Filings.
July 5, 2022
UC Davis Professor Jane Sykes presents a webinar on a multi-center study using the MiQLab to diagnose urinary tract infections
July 1, 2022
LexaGene is pleased sell a MiQLab System into a veterinary hospital in Wisconsin.
June 30, 2022
LexaGene was granted a management cease trade order while it prepares its year-end financial statements for Canada.
June 28, 2022
LexaGene has filed an initial registration statement with the United States Securities and Exchange Commission (the “SEC”) on Form 10 under the United States Securities Exchange Act of 1934.
May 25, 2022
LexaGene is pleased to announce a large veterinary animal health corporation has purchased two MiQLab® Systems for two of their locations.
May 3, 2022
The U.S. Army Combat Capabilities Development Command Chemical Biological Center (DEVCOM Chemical Biological Center) has successfully completed the evaluation of the MiQLab System for biothreat detection.
For Marketing inquiries, please email: